Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27514789 | 0.81 | MAPT (0.43) | MAPTHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5871715 | 0.78 | PTPRB (0.41) | — | |
| SCHEMBL5872106 | 0.77 | PPARG (0.40) | HPGDSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5871875 | 0.77 | ESR1 (0.39) | — | |
| SCHEMBL5871796 | 0.76 | PPARG (0.39) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5872194 | 0.76 | ACHE (0.39) | HPGDMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL5871908 | 0.76 | MAPT (0.46) | MAPTHPGDSMN1; SMN2NPSR1NTSR1 | |
| SCHEMBL5871983 | 0.76 | MAPT (0.46) | MAPTHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11503972 | 0.75 | MAPT (0.43) | MAPTHPGDSMN1; SMN2NPSR1NTSR1 | |
| SCHEMBL5872251 | 0.75 | MAPT (0.45) | MAPTHPGDSMN1; SMN2NPSR1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214853-A1 | Naphthyridine derivatives | MT-ND1, OPRD1, NR0B1 | MAPT 2184/4885HPGD 1690/4885MEN1 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.